张立行 副研究员 副研究员，博士生 E-mail: Zhanglixing601@163.com

     2006年毕业于中国医科大学获得法医学学士学位，2009年毕业于南昌大学医学院获得细胞生物与分子生物学硕士学位，2012年毕业于上海交通大学医学院获得肿瘤学博士学位。2012年-2016年在上海市肿瘤研究所癌基因及相关基因国家重点实验室工作。2016年8月至今任职于复旦大学附属肿瘤医院肿瘤研究所。近5年主持项目包括国家自然科学基金青年基金、面上项目各一项，教育部高校博士点基金项目一项，作为骨干参与科技部重点研发计划一项并参与多项国家科技重大专项研究工作。近5年主要研究成果发表于Advanced Science, Cancer Research, PLOS Biology, Theranostics, Cell Death & Differentiation, Scientific Reports, Molecular Medicine, Chinese Journal of Cancer等杂志。

研究领域：

　　1. 乳腺肿瘤干细胞自我更新与分化的调控机制研究； 
　　2. 乳腺肿瘤干细胞与免疫微环境的相互作用与靶向治疗研究；
　　3. 肿瘤干细胞参与化疗抵抗的内源性与外源性调控与转化研究。

代表性论著：

1. Zhang LX^# , Qiang J^# , Yang L^# , Wang D, Adeel R, He X, Chen W, Sheng D, Zhou L, Jiang YZ, Li T, Du Y, Feng J, Hu X, Zhang J, Hu XC, Shao ZM, Liu S^*. IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability. Advanced Science, 2020; 7(1): 1901728.

2. Zhou L^#, Wang D^#, Sheng D^#, Xu J, Chen W, Qin Y, Du R, Yang X, He X, Xie N^*, Liu S^*, Zhang LX^*. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics, 2020; 10(5):2405-2421.

3. Wang D^#, Xu J^#, Liu B, He X, Zhou L, Hu X, Qiao F, Zhang A, Xu X, Zhang H, Wicha MS, Zhang LX, Shao ZM, Liu S^*. IL6 blockade potentiates the anti-tumor effects of γ–secretase inhibitors in Notch3-expressing breast cancer. Cell Death & Differentiation, 2018; 25(2):330-339.

4. Chen W^#, Qin Y^#, Wang D, Zhou L, Liu Y, Chen S, Yin L, Xiao Y, Yao XH, Yang X, Ma W, Chen W, He X, Zhang LX, Yang Q, Bian X, Shao ZM, Liu S^*. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biology, 2018; 16(7):e2005869.

5. Zhang Y^#, Zhang LX^#, Liu XQ, Zhao FY, Ge C, Chen TY, Yao M, Li J^*. Id4 promotes cell proliferation in hepatocellular carcinoma. Chinese Journal of Cancer, 2017; 36(1):19.

6. Zhang LX, Ge C, Zhao FY, Zhang Y, Wang X, Yao M, Li J^*. NRBP2 interactes with ANXA2 render hepatocellular carcinoma cell sensitive to apoptosis through Akt signaling pathway. Cancer Research，2016; 76(23):7059-7071.

7. Zhang L^#, Zhang LX^#, Li H, Ge C, Zhao FY, Tian H, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J^*. CXCL3 contributes to CD133+ CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Scientific Report, 2016; 6:27426.

8. Zhang LX, Sun HF, Zhao FY, Lu P, Ge C, Li H, Hou H, Yan M, Chen T, Jiang G, Xie H, Cui Y, Huang X, Fan J, Yao M, Li J^*. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Research, 2012; 72(16):4276-4285.

9. Lu P, Sun HF, Zhang LX, Hou H, Zhang L, Zhao F, Ge C, Yao M, Wang T, Li J^*. Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Molecular Medicine, 2012; 18:1136-1146.